Oregon Investment, E Hlalositsoe Hantle
Ho latela PharmOutsourcing e fana ka phatlalatso ea phatlalatso ea Lonza, ho Koba, Setsi sa Oregon se tla kenya likarolo tse peli tsa PSD-4 tsa ho omisa ka sekhahla sa khoebo, e nang le sebaka sa ho eketsa bokhoni ba nako e tlang. Ho lebeletsoe ho phethela hohle 2029. Setsi sena se shebane le li-dispersions tse omisitsoeng (SDD) - mokhoa oa boenjiniere ba meriana o fetolang limolek'hule tse nyane tsa BCS tsa Sehlopha sa II le IV hore e be li-amorphous solid dispersions tse nang le bioavailability e ntlafalitsoeng ka mokhoa o hlakileng.. Lonza e tšoaea matsete e le ho sebetsana le lekhalo le ntseng le tsoela pele la khoebo la SDD indastering.
Ho omisa ka sekala sa PSD-4 ha se theknoloji ea sefofane. Ke lisebelisoa tsa tlhahiso ea lihlahisoa tsa ho qetela tse etselitsoeng ho ts'ehetsa mananeo a liteko tsa kliniki tsa morao-rao le phepelo ea khoebo. Khetho ea Bend, Oregon - sebaka se teng sa Lonza seo o phethetse katoloso e tiileng ea tlhahlobo ea foromo ho Q4 2022 - e tiisa hore sena ke moaho oa setsi sa lihlahisoa tsa limolek'hule tse nyane tsa US tsa US, eseng greenfield bokgoni push.
Bakeng sa moelelo oa seo setsi sena se etselitsoeng ho se sebetsa: Spray-omisitsoeng dispersions hloka hore mafolofolo meriana motsoako (API) e se e ntse e le teng ka bongata bo lekaneng le bohloeki ho ts'ehetsa nts'etsopele ea ts'ebetso le tlhahiso ea bongaka. Nakong eo molek'hule e kenang tlhahiso ea SDD ea khoebo, e tlositse lilemo tse ngata tsa ho qaptjoa ha pele, tlhatlhobo ya sebopeho, tlhahlobo ea tlhahiso, le tlhahlobo ea taolo. Setsi sa Oregon se qala moo ho sibolloa le nts'etsopele ea pele ho tleliniki e fellang teng.
Seo Tatelano ea Libeche tsa Lidolara tse Libilione e Se Senolang
Phatlalatso ea Oregon e lumellana le mokhoa o lumellanang oa kabo ea morao-rao ea capital ea Lonza e lokelang ho baloa ka botlalo.:
-
Vacaville, California: A $1.2 bilione ea ho fumana sebaka se seholo sa mammalian biologics sa Roche, e lateloe ke CHF e eketsehileng 500 matsete a katoloso ea limilione, e shebileng tlhahiso ea lithethefatsi tse anyesang tsa khoebo - e hlalosoang ke Lintlha tsa DCAT Value Chain (2025) joalo ka sepheo sa Lonza sa ho hapa tlhoko e kholo ea bioloji
-
Peptide Synthesis Hlakola, Switzerland: CHF 500 milione setsing sa ho tlatsa le ho qeta bakeng sa lithethefatsi tsa biologic; katoloso e arohaneng ea matla a bioconjugation e lebisitseng tlhahiso ea khoebo ea ADC
-
Portsmouth, New Hampshire: CHF 200 limillione lits'ebetsong tsa biomanufacturing bakeng sa phepelo ea litleleniki tse nyane ho isa bohareng le tsa pele tsa khoebo.
-
Kobeha, Oregon: Ho omisa ka mokhoa oa khoebo oa PSD-4 bakeng sa tlhahiso ea lihlahisoa tsa lithethefatsi, ho qetela ~2029, joalo ka PharmaNoW (2026) tlaleha, ho shebisisa lekhalo le tsitsitseng la bokhoni ho tlhahiso ea SDD ea khoebo
Mabaka a kopanyang matsete ana ke tsoelopele ea phepelo maemong a khoebo. Joalo ka Tlhahlobo ea BioPharma ea ho fumana Vacaville hlokometsoe, Leano la Lonza ke ho ipeha e le molekane oa tlhahiso eo bareki ba biopharma ba lulang le eena ha mananeo a ntse a tsoela pele ho tloha ka kliniki ho ea qala le ho feta - eseng haholo-holo e le molekane oa k'hemistri ea tlhahlobo ea pele..
Letšoao la 'maraka tatellano ena e romella: matsete a tsoang kantle a tlhahiso ea biomanufacturing a tsepamisitse maikutlo qetellong ea lipeipi tsa ntlafatso. Mananeo a bohlokoa ho aha meaho bakeng sa ke ona a nang le mekhoa e hlakileng ea khoebo. Mosebetsi oa ho sibolla pele le o nolofalletsang IND - ho pheta-pheta ka potlako, lihlopha tse nyane, k'hemistri e tloaelehileng, le sebopeho se tebileng sa tlhahlobo - e sebetsa sebakeng se fapaneng sa litšebeletso, e 'ngoe eo li-CDMO tse kholo tse kopantsoeng ha li iketsetse kapa li theko e phahameng ka ho fetesisa.
Letšoao la senotlolo: Letsete la Oregon la Lonza le tiisa hore li-CDMO tse kholo ka ho fetisisa li hokahanya bokhoni ba tsona mabapi le tsoelopele ea bongaka ho isa khoebong.. Sena ke sebopeho, eseng ea nakoana - mme e hlakisa hore na ke mefuta efe ea balekane e sebeletsang mekhahlelo efe ea lipeipi.
Biomanufacturing Spectrum e na le Bifurcating, Eseng Ho Kopanya
Ho baloa ka mokhoa o hlakileng ho matsete a maholo a CDMO ke ho kopana: libapali tse kholo li monya ho feta 'marakeng, litsebi tse nyane li kopanya kapa lia tsoa. 'Nete ea ts'ebetso bakeng sa nts'etsopele ea peptide e tsamaea ka tsela e fapaneng. Ha mananeo a ntse a hola ka ho rarahana le litlhoko tsa phetoho ea li-analogue tsa GLP-1, li-peptide tse tloaelehileng, mme meputso ya ADC e a ntlafala, lekhalo la tekheniki lipakeng tsa li-CDMO tse kholo tsa tlhahiso le balekane ba khethehileng ba k'hemistri ea sibollo le eketsehile ho fapana le ho koaloa.
Mokhoa o sebetsang oa ho etsa khetho ena ke khetho eo Lethathamo la litšebeletso tsa CDMO tsa Lethathamo la Peptide draws between research-phase services (tloaelo ea synthesis, non-GMP analytical testing for early sequences) and CMC development services (nts'etsopele ea ts'ebetso, GMP preparation, ho phahamisa). These two service layers require different equipment, different staff competency profiles, and different quality systems — and they are increasingly served by distinct organizations.
The table below captures how specialized peptide CDMOs differentiate from large-scale manufacturers across the dimensions that matter most to early-stage development teams:
|
Boemo |
Large Integrated CDMO (Lonza-type) |
Specialized Peptide Synthesis Partner |
|---|---|---|
|
Primary development stage |
Phase II through commercial |
Discovery through IND-enabling |
|
Batch scale |
Kilogram to multi-hundred kilogram |
Milligram to gram, with kg-scale pathway |
|
Synthesis modalities |
Platform-based (mammalian, microbial, SDD) |
SPSS, LPPS, hybrid condensation, ho belisoa ha likokoana-hloko |
|
Modification portfolio |
E fokotsehile ka har'a li-platform tse thehiloeng |
E pharaletseng: 300+ lihlopha tse sebetsang, tloaelo ha e batloa |
|
Moetso oa phetoho |
Nako e telele e hlophisitsoeng |
Ho pheta-pheta ka potlako; libeke eseng kotara |
|
Ho kopanngoa ha tlhahlobo |
tlhahlobo ea tokollo ea cGMP |
Mokhoa oa ntlafatso oa Orthogonal, ho hlahisa ditshila, netefatso ya sebopeho |
|
Boemo ba ho beleha |
Kamore e hloekisitsoeng ea GMP |
Sehlopha 100 tikoloho e hloekileng haholo bakeng sa lisebelisoa tsa tlhahlobo ea lisele |
|
CTA / sebopeho sa taolo |
Ts'ehetso e felletseng ea NDA/BLA CMC |
Litokomane tse nolofalletsang IND; Sephutheloana sa boleng ba CoA-level |
Ha ho boemo bo holimo ho feta bohle. Ba sebeletsa linako tse fapaneng tsa liphaephe, 'me litšenyehelo tse sa lumellaneng li phalla ka mahlakoreng ka bobeli: Ho kenya letsoho CDMO e kholo e kopantsoeng bakeng sa motsoako o potlakileng oa ho sibolla ho hlahisa kemiso e holimo le litlhoko tse fokolang tsa batch tse liehang ho pheta-pheta.; ho sebelisana le mofani oa lihlahisoa tsa lipatlisiso bakeng sa tlhahiso ea khoebo ho hlahisa kotsi e sa amoheleheng ea taolo. Phoso ea liqeto ke ho tšoara 'maraka oa CDMO joalo ka karolo e le' ngoe.
Litšebeletso tsa Ketane ea Pele tse Lulang Tseleng ea Litsebi
Mohaho oa Oregon oa Lonza o tla qetella o sebetsana le lihlahisoa tsa lithethefatsi tseo API ea tsona e kopaneng le tlhahlobo ea sebopeho e etsahetseng lilemo tse fetileng, hangata mekhatlong e khethehileng ea k'hemistri. Ho utloisisa hantle hore na ke litšebeletso life tse amanang le ketane eo ea pele ho hlakisa hore na setsi sa ho omisa se etsa eng. eseng nkela sebaka.
Discovery-grade le IND-enable synthesis. Ntho ea mantlha e ka fanoang mothating ona ke e netefalitsoeng, tatellano ea peptide e khetholloang ka mokhoa o hlakileng ka bohloeki bo lekaneng le bongata bakeng sa in vitro le in vivo pharmacology.. Mokhoa o ikhethileng oa peptide synthesis sekala sa lipatlisiso se hloka ntlafatso ea mokhoa oa SPPS bakeng sa hydrophobic, pokeletso-tlase, le tatelano ya ketane e telele, e lateloe ke tlhoekiso ea RP-HPLC e itokisang, lyophilization, le litokomane tse felletseng tsa CoA. Bonyane-batch ba sebetsang ho tloha ho 1 mg bakeng sa tlhahlobo ea pele ea ho 500 mg bakeng sa lithuto tsa pele tsa pharmacokinetic - lipalo tse oelang ka tlase ho moeli oa moruo bakeng sa boitlamo ba CDMO.
Khemistri ea phetoho. Sebaka sa kalafo se tsamaisang matsete a CDMO - GLP-1 receptor agonists, ADC e lefa chelete e ngata, li-peptide tse tloaelehileng, li-macrocycles tse fumanehang ka molomo - kaofela li hloka k'hemistri e fetotsoeng e fetang tatellano e tloaelehileng.. The phetolo ea peptide le lits'ebeletso tsa tlhahlobo e batloang nakong ea ho sibolloa le mekhahlelo ea pele ho kliniki e kenyelletsa:
-
Isotope labeling: ¹³C, ¹⁵N, ²H, le ¹⁸O kenyeletso bakeng sa tlhahlobo ea bioanalysis ea LC-MS/MS, Lithuto tsa DKIE, le liteko tse tsitsitseng tsa isotope dilution. Matlafatso ea Isotopic ≥99% ke maemo a tloaelehileng bakeng sa lits'ebetso tsa kliniki tsa biomarker.
-
Leibole la fluorescent: FITC, FAM, TAMRA, Cy3, Cy5, le ho kenya FRET para bakeng sa liteko tsa ho nka lisele, lithuto tse tlamang li-receptor, le litšoantšo tsa confocal. Boemo ba sehokelo sa dae le katleho ea ho tima li hloka netefatso ea orthogonal ke HPLC le spectrophotometry..
-
Lipidation le PEGylation: Palmitoylation, myristoylation, le kopano e khethehileng ea sebaka sa PEG bakeng sa katoloso ea halofo ea bophelo ho GLP-1 le mananeo a mang a metabolic peptide..
-
Ho tsamaea ka baesekele: Disulfide, lactam, thioether, le ho theha lik'hemik'hale bakeng sa thibelo ea conformational le ntlafatso ea botsitso ba protease.
-
Click-chemistry handles: Azide, alkyne, DBCO, le ts'ebetso ea BCN bakeng sa bioconjugation e khethang sebaka sa nts'etsopele ea lihokelo tsa ADC le kaho ea probe ea litšoantšo..
Analytical QC le sebopeho. Li-peptide tsa nts'etsopele ea pele li hloka boitsebiso le netefatso ea bohloeki pele ho tlhahlobo efe kapa efe ea baeloji, eseng joalo ka mokhoa oa taolo empa joalo ka tlhoko ea saense. Peptide ea lipatlisiso e sa sebetseng hantle kapa e fapaneng ea lik'hemik'hale e hlahisa lintlha tse sa tšepahaleng tsa pharmacology tse khelosang lenaneo lohle.. Sephutheloana sa analytical mothating ona hangata se kenyelletsa: RP-HPLC bohloeki quantification ka 214 nm le 254 nm, ESI-MS kapa MALDI-TOF netefatso ea boima ba limolek'hule, tlhahlobo ea amino acid bakeng sa netefatso ea tatellano, le - bakeng sa lisebelisoa tse reretsoeng liteko tse thehiloeng liseleng - tlhahlobo ea endotoxin ho USP ⟨85⟩ LAL meeli. Lisebelisoa tsa peptide tsa sele-assay-grade tse tsoang ho Sehlopha 100 sterile synthesis tikoloho ka botshepehi e kopana le menyako ya endotoxin (ka tlwaelo <1 EU/mg) seo baeloji ea lisele le lihlopha tsa pharmacology tsa in vivo li li hlokang. Sena ha se bokhoni bo fumanehang ka tšohanyetso litsing tsa khoebo tsa lihlahisoa tsa lithethefatsi tse etselitsoeng ts'ebetso ea ho qetela.
Tlhaloso ea ho se hloeke le taolo ea mefuta-futa ea sebopeho. Peptide structural microheterogeneity - deamidation, oxidation, racemization, thitelo, le aggregation byproducts - e fetoha kotsi ea CMC ha mananeo a ntse a tsoela pele. Ho sebetsana le eona ka tlhahlobo nakong ea ho sibolloa, ho sebelisa mekhoa ea orthogonal chromatographic (C18, C4, diphenyl) le limmapa tse nang le liphetho tse phahameng tsa ESI-MS, e theko e tlase haholo ho feta ho e fumana nakong ea tlhahlobo ea batch ea IND.
Matrix ea Khetho ea Mohato ka Mothati
Se boleloang ke ts'ebetso ea bifurcation e hlalositsoeng ka holimo ke sebopeho sa tšebelisano-'moho, moo mofuta o nepahetseng oa CDMO o fetohang ha lenaneo le ntse le tsoela pele. Matrix e ka tlase e hula lekhetho la lits'ebeletso tse sebelisoang ho pholletsa le lekala la peptide synthesis mme e lokela ho sebetsa joalo ka sesebelisoa sa pele sa ho tsamaisa., ha se tataiso e hlakileng ea ho reka. The mekhoa ea khetho ea balekane e fetang bokhoni - tsebo ea ho fetola, botebo ba ho sekaseka, boleng ba puisano botekgeniki, le litekanyetso tsa litokomane - li lokela ho hlahlojoa ka har'a mokhahlelo o mong le o mong pele ho puisano.
|
Mohato oa Nts'etsopele |
E ka Nehelanoang ka Pele |
Mofuta o Loketseng oa Molekane |
Tšoaneleho ea Bohlokoa Li-Peptide tsa Synthetic Litekanyetso |
|---|---|---|---|
|
Ho sibolloa / Tobetsa Identification |
Li-peptide tsa lipatlisiso tse fetotsoeng, ho hlahloba lilaebrari, li-reagents tsa tlhahlobo |
Lab e khethehileng ea synthesis (sehlopha sa lipatlisiso) |
Phetoho ea bophara ba potefolio, HPLC/MS CoA boleng, lebelo la phetoho (2-4 libeke tse tloaelehileng) |
|
Ntlafatso ea Pele |
SAR-iteration lihlopha, litekanyetso tsa isotope, lipatlisiso tsa pharmacokinetic |
Special synthesis lab e nang le bokhoni bo matla ba ho sekaseka |
Isotope labeling precision, taolo ea endotoxin bakeng sa liteko tsa lisele, ≥95% bohloeki ka netefatso e felletseng ea MS |
|
Pele ho tleliniki / IND-E nolofalletsa |
cGMP kapa li-batch tse kang cGMP bakeng sa lithuto tsa toxicology, Litokomane tsa CMC Tlhahiso ea Peptide |
CDMO e shebaneng le Peptide (ka sistimi ea boleng ba boemo ba GMP) |
Mokhoa oa setifikeiti sa GMP, bokhoni ba lenaneo la botsitso, Tšehetso ea litokomane tsa IND CMC |
|
Mokhahlelo oa I–II |
Lihlopha tsa GMP API, ntho ea meriana ea kliniki, netefatso ya mokgwa |
Peptide CDMO e nang le rekoto ea taolo ea pina |
Ho latela melao ea ICH Q7, boiphihlelo ba ho kenya lifaele, Tšehetso ea tlhahiso ea CTA/IND |
|
Mokhahlelo oa III / Tsa khoebo |
E kholo ea GMP API, tlhahiso ea lihlahisoa tsa lithethefatsi, phepelo tsweletso |
CDMO e kholo e kopantsoeng (Lonza, Sekala sa khoebo sa Bachem) |
Bokhoni ba khoebo, khaello ea phepelo, histori ea tlhahlobo ea taolo |
Qeto ea bohlokoa ha se hore na lenaneo le hloka boemo bofe empa le hloka boemo bofe jwale. Boithuto bo nolofaletsang IND bo hloka molekane oa boemo 3, eseng tier 5. Mothati o kopanyang 5 meaho bakeng sa maemo 2 mosebetsi o hlahisa tlhahiso ea thepa, boitlamo ba bonyane ba sehlopha, le ho hlophisa latency eo kemiso ea nako ea tšibollo e ke keng ea e amohela.
The Counterargument - le Moo e oelang haufinyane
Taba e utloahalang ka ho fetesisa tlhahlobisong e kaholimo ke hore Lonza e na le bokhoni ba k'hemistri ea limolek'hule le lits'ebeletso tsa tlhahiso tse amanang le peptide.. Sebaka sa eona sa Visp se sebetsana le lithethefatsi tsa peptide ka har'a mananeo a bioconjugate; sethala sa eona se senyenyane sa limolek'hule se tšehetsa nts'etsopele ea API bakeng sa lithethefatsi tse rarahaneng tsa maiketsetso. Sena se nepahetse 'me se lokela ho amoheloa ka ho toba.
Phapang e setseng, leha ho le joalo, ke e 'ngoe ea optimization le scope. Sethala sa limolek'hule tse nyane tsa Lonza se etselitsoe ho potoloha k'hemistri ea ts'ebetso bakeng sa li-API tse thehileng tse lebisang tlhahisong ea GMP - ho hlahloba litsela le ho ntlafatsa mananeo a seng a ntse a e-na le mokhethoa le moralo oa nts'etsopele.. Discovery-phase peptide synthesis, ka ho fapana, e hloka mohlala oa litšebeletso o hahiloeng bakeng sa ho pheta-pheta ka potlako: tatellano e tloahelehileng ka tatellano e tloahelehileng, e nang le litumello tsa phetoho tse ka balang ka bongata letotong le le leng, le ka phetoho ea tlhahlobo e lekantsoeng ka matsatsi ho feta libeke. Meaho ea motheo ea khoebo e etsang hore GMP bioreactor kapa PSD-4 spray-dryer e sebetse moruong ke eona meaho e etsang hore e se be litšenyehelo bakeng sa k'hemistri e tloaelehileng ea milligram..
Ho etsa lihlahisoa tse omisitsoeng ka spray ho boetse ho hloka hore bothata ba k'hemistri ea API bo rarolloe pele tlhahiso e qala. Motsoako o fihla setsing sa PSD-4 se Bend, Oregon ka 2030 e tla be e entsoe, hloekisitsoe, ea khetholloa, le botsitso-profiled ke mekhatlo eo bokhoni ba eona ba mantlha e leng mosebetsi oo oa k'hemistri ea holimo. Mekhatlo eo le setsi sa Oregon ha se tse nkang sebaka - ke li-node tse latellanang mokotleng o le mong oa nts'etsopele.
'Nete ea sebopeho: li-CDMO tse kholo le balekane ba khethehileng ba peptide synthesis ha ba qothisane lehlokoa bakeng sa mosebetsi o tšoanang. Ba sebeletsa linako tse fapaneng tsa liphaephe, mme matsete a Lonza a Oregon a tiisa ntlha eo ka ho bonts'a hantle hore na CDMO ea sekala seo e ntlafatsa nako efe..
Ho bala Letšoao la Mmaraka ka nepo
Phatlalatso ea Lonza ea Oregon ha se tšokelo ea ho kopanya ho bafani ba khethehileng ba peptide synthesis. Ke netefatso ea hore 'maraka oa lihlahisoa tsa lihlahisoa tsa tlhaho o ntse o hola ka tsela e fanang ka moputso o ikhethang lipheletsong tse peli tsa lipeipi..
Bakeng sa peptide R&D ba etsang liqeto, liphello tse sebetsang ke tse tobileng:
-
Liqeto tsa ho fumana chelete esale pele (ho sibolla ka ho nolofaletsa IND) ba ka har'a lane ea litsebi - balekane ba nang le k'hemistri ea phetoho e tebileng, ka potlako-iteration synthesis workflows, bokhoni ba ho hlahloba orthogonal, le tlhahiso e hloekisitsoeng e laoloang ke endotoxin bakeng sa thepa ea boemo ba lisele.
-
Ho fumana mothati o bohareng ho isa morao (Phase I ho ea khoebong) ke ea li-CDMO tse nang le lisebelisoa tsa motheo tsa GMP, boiphihlelo ba ho kenya lifaele, le tsoelo-pele ea phepelo e hlokehang ke lenaneo la khoebo.
-
Qeto ea ho sebelisana le maemo afe kapa afe pele a loketse ha e hloke litšenyehelo. Ho kenya letsoho pele ho nako ea lisebelisoa tsa khoebo tsa CDMO ho liehisa ho pheta-pheta pele ho nako; letsoho la pele ho nako ho tloha ho sehlopha sa lipatlisiso ho ea ho GMP pele ho ikemisetsa ha CMC ho hlahisa kotsi ea taolo..
Setsi sa ho omisa ka spray Lonza se aha Bend, Oregon e tla sebetsana le lihlahisoa tsa lithethefatsi tse qalileng e le menahano ea tatellano e entsoeng ka milligram scale, e tšoauoa ka HPLC le ESI-MS, e phetoa ka litumello tse ngata tsa phetoho, 'me e tsoetse pele ka mosebetsi oa pele ho tleliniki le oa bongaka ka lilemo. Mosebetsi oo oa pele-pele o etsahala setsing se fapaneng, tlas'a tsamaiso e fapaneng ea boleng, le molekane ya fapaneng.
Itokiselitse ho lekola hore na tatellano ea hau e se e loketse mohato o latelang oa nts'etsopele?
Liphetoho tsa MOL li fana ka peptide synthesis, phetoho, le sebopeho sa tlhahlobo ho tloha ho sibolloa ka sekala se nolofalletsang IND, ho kenyelletsa le ho ngola li-isotope tse tsitsitseng, ho kenya label ea fluorescent, lisebelisoa tsa sterile cell-grade tse nang le tlhahlobo ea endotoxin, le ho tlatsa litokomane tsa HPLC/MS CoA. Ikopanye le sehlopha sa tekheniki ho buisana ka monyetla oa tatellano, likhetho tsa ho fetola, kapa litlhoko tsa hau tsa tlhahlobo ea mangolo.
Litšupiso tse ling: Lonza e Phetha Katoloso ea Litšebeletso tsa Foromo e Tiileng (Lonza.com, Pherekhong 2023); Lonza Plans Oregon Spray-Drying Setsi sa Ntlafatso ea Lithethefatsi le Tlhahiso (PharmOutsourcing, 2026); PharmaNoW, 2026; Seo Lonza's $1.2B e Rekang Semela sa Roche Biologics se Se Bolelang Bakeng sa Mmaraka oa CDMO (BioPharma, 2024); Lintlha tsa DCAT Value Chain, 2025; Litšebeletso tsa Peptide CDMO ka Stage (Lethathamo la Peptide, 2026)
